In trading on Tuesday, utilities shares rose by just by 1.1%. Walgreens Boots Alliance Inc WBA on Tuesday reported better-than-expected earnings for its second quarter. The company posted second ...

(KFSN) -- A man is in custody after a deadly shooting in Madera. It happened just after 9:30 pm Monday at the Walgreens on Cleveland and Schnoor. Police were called about a person they say ...

The SOUL (NCT03914326) clinical trial is the first to assess the cardiovascular benefits of an oral GLP-1 inhibitor, building on its effectiveness aligns with injectable formulations.

During the struggle, she said he grabbed his bag and took out a syringe and tried to inject her. "I do not know what was in the syringe, but Gerhardt is an anesthesiologist and has access to ...

Given these positive results, once-daily oral PL8177 could be a safe and effective ... www.Palatin.com and follow Palatin on Twitter at @PalatinTech. 1 Lewis JD, Parlett LE, Jonsson Funk ML, et al.

No­vo Nordisk is go­ing all-in on next-gen­er­a­tion obe­si­ty med­i­cines, and on Fri­day an­nounced a li­cens­ing deal with a Texas biotech to get ac­cess to its … ...

Given these positive results, once-daily oral PL8177 could be a safe and effective ... stool frequency subscore = 0 or 1, and endoscopy subscore = 0 or 1. Clinical response (statistically ...

Medical experts warn the move could have consequences for oral health, especially among children. By Melinda Wenner Moyer Utah has become the first U.S. state to outlaw the addition of fluoride to ...

Novo Nordisk has signed a deal worth up to $1bn with Lexicon Pharmaceuticals for the exclusive global rights to LX9851, an experimental oral treatment for obesity ... its blockbuster glucagon-like ...

The United States Department of Agriculture will distribute oral rabies vaccine by aircraft across Northwest Georgia from April 7-15. This operation is part of a nationwide effort by USDA to ...

Eli Lilly is gearing up for a breakthrough in diabetes and obesity treatment with its upcoming oral GLP-1 drug, orforglipron. In an exclusive conversation with CNBC-TV18’s Shereen Bhan, the company’s ...

with a unique binding mode from previously reported WRN inhibitors Phase 1 dose escalation trial ongoing in MSI-H solid tumors with GSK MSI-H prevalence has been reported at approximately 31% ...